The lack of clinical efficacy of dasatinib in Ewing sarcoma patients is in line with the tumor-promoting role for the prevention of Src hyperactivation by GDF6-CD99 signaling in Ewing sarcoma. This evidence concerns the gene GDF6 and Ewing sarcoma.